Founded in 2011, Elicio Therapeutics Inc. strives to use precision vaccines, immunomodulators and cell-based therapies to assemble cancer-killing immune responses against both blood and solid tumors. <br /><br />Elicio’s proprietary Amphiphile or “AMP” platform differentiates the company through the development of cancer immunotherapies for patients with limited treatment options and often poor outcomes. <br /><br />As the foundation for the various vaccine candidates in the biotech company’s pipeline, the AMP platform will help Elicio combat cancer and other diseases.
